<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04895592</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00001896</org_study_id>
    <secondary_id>NCI-2021-02761</secondary_id>
    <secondary_id>STUDY00001896</secondary_id>
    <secondary_id>RAD5234-21</secondary_id>
    <secondary_id>P30CA138292</secondary_id>
    <nct_id>NCT04895592</nct_id>
  </id_info>
  <brief_title>Radiosurgery Before Surgery for the Treatment of Brain Metastases</brief_title>
  <official_title>Preoperative Radiosurgery for Brain Metastases Planned for Surgical Resection: A Two Arm Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This early phase I trial identifies the side effects of stereotactic radiosurgery before&#xD;
      surgery in treating patients with cancer that has spread to the brain (brain metastases).&#xD;
      Radiation may stimulate an anti-tumor immune response. Giving stereotactic radiosurgery&#xD;
      before surgery may reduce the risk of the cancer coming back after surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To determine the safety of pre-operative stereotactic radiosurgery (SRS) followed by&#xD;
      surgery for brain metastasis.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the immune niche in brain metastasis following SRS in the presence of low or&#xD;
      high dose dexamethasone.&#xD;
&#xD;
      II. To evaluate the impact of pre-operative SRS on survival outcomes.&#xD;
&#xD;
      OUTLINE: Patients are assigned to 1 of 2 arms.&#xD;
&#xD;
      ARM A: Patients undergo SRS to the brain metastasis for 1-3 fractions over 1-5 days. Patients&#xD;
      also receive low dose dexamethasone orally (PO) or intravenously (IV) for 2-21 days until the&#xD;
      day of surgical resection. Patients then undergo surgical resection.&#xD;
&#xD;
      ARM B: Patients undergo SRS to the brain metastasis for 1-3 fractions over 1-5 days. Patients&#xD;
      also receive high dose dexamethasone PO or IV for 2-21 days until the day of surgical&#xD;
      resection. Patients then undergo surgical resection.&#xD;
&#xD;
      After completion of study intervention, patients are followed up for 120 days, and then every&#xD;
      12 weeks thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 20, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events grade 3 or greater</measure>
    <time_frame>At 4 months post-treatment</time_frame>
    <description>Evaluated using Common Terminology Criteria for Adverse Events. Tolerability of this regimen will be defined as &lt; 33% of patients develop grade &gt; 3 at 4 months. Adverse events will be summarized descriptively using frequencies and percentages.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Density of immune niche in brain metastases</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Niche density will be assessed by immunofluorescence as described above. It will be summarized descriptively as the percent of tumor occupied by immune niche for each treatment arm, and will be compared between Arms A and B using a two-sample t-test or non-parametric equivalent, such as Mann-Whitney U test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to local recurrence (LR)</measure>
    <time_frame>From pre-operative stereotactic radiosurgery (SRS) to intracranial progression at the treated site, assessed up to 2 years</time_frame>
    <description>LR will be estimated using the Kaplan-Meier method, and a 95% confidence interval for median LR will be estimated using the Brookmeyer-Crowley approach.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to anywhere brain failure (ABF)</measure>
    <time_frame>From preoperative SRS to intracranial progression at any site within the brain, assessed up to 2 years</time_frame>
    <description>ABF will be estimated using the Kaplan-Meier method, and a 95% confidence interval for median TBF will be estimated using the Brookmeyer-Crowley approach.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From pre-operative SRS initiation to death, assessed up to 2 years</time_frame>
    <description>OS will be estimated using the Kaplan-Meier method, and a 95% confidence interval for median OS will be estimated using the Brookmeyer-Crowley approach.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Metastatic Malignant Neoplasm in the Brain</condition>
  <condition>Metastatic Malignant Solid Neoplasm</condition>
  <arm_group>
    <arm_group_label>Arm A (SRS, low dose dexamethasone, surgery)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo SRS to the brain metastasis for 1-3 fractions over 1-5 days. Patients also receive low dose dexamethasone PO or IV for 2-21 days until the day of surgical resection. Patients then undergo surgical resection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (SRS, high dose dexamethasone, surgery)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo SRS to the brain metastasis for 1-3 fractions over 1-5 days. Patients also receive high dose dexamethasone PO or IV for 2-21 days until the day of surgical resection. Patients then undergo surgical resection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Given PO or IV</description>
    <arm_group_label>Arm A (SRS, low dose dexamethasone, surgery)</arm_group_label>
    <other_name>Aacidexam</other_name>
    <other_name>Adexone</other_name>
    <other_name>Aknichthol Dexa</other_name>
    <other_name>Alba-Dex</other_name>
    <other_name>Alin</other_name>
    <other_name>Alin Depot</other_name>
    <other_name>Alin Oftalmico</other_name>
    <other_name>Amplidermis</other_name>
    <other_name>Anemul mono</other_name>
    <other_name>Auricularum</other_name>
    <other_name>Auxiloson</other_name>
    <other_name>Baycadron</other_name>
    <other_name>Baycuten</other_name>
    <other_name>Baycuten N</other_name>
    <other_name>Cortidexason</other_name>
    <other_name>Cortisumman</other_name>
    <other_name>Decacort</other_name>
    <other_name>Decadrol</other_name>
    <other_name>Decadron</other_name>
    <other_name>Decadron DP</other_name>
    <other_name>Decalix</other_name>
    <other_name>Decameth</other_name>
    <other_name>Decasone R.p.</other_name>
    <other_name>Dectancyl</other_name>
    <other_name>Dekacort</other_name>
    <other_name>Deltafluorene</other_name>
    <other_name>Deronil</other_name>
    <other_name>Desamethasone</other_name>
    <other_name>Desameton</other_name>
    <other_name>Dexa-Mamallet</other_name>
    <other_name>Dexa-Rhinosan</other_name>
    <other_name>Dexa-Scheroson</other_name>
    <other_name>Dexa-sine</other_name>
    <other_name>Dexacortal</other_name>
    <other_name>Dexacortin</other_name>
    <other_name>Dexafarma</other_name>
    <other_name>Dexafluorene</other_name>
    <other_name>Dexalocal</other_name>
    <other_name>Dexamecortin</other_name>
    <other_name>Dexameth</other_name>
    <other_name>Dexamethasone Intensol</other_name>
    <other_name>Dexamethasonum</other_name>
    <other_name>Dexamonozon</other_name>
    <other_name>Dexapos</other_name>
    <other_name>Dexinoral</other_name>
    <other_name>Dexone</other_name>
    <other_name>Dinormon</other_name>
    <other_name>Dxevo</other_name>
    <other_name>Fluorodelta</other_name>
    <other_name>Fortecortin</other_name>
    <other_name>Gammacorten</other_name>
    <other_name>Hemady</other_name>
    <other_name>Hexadecadrol</other_name>
    <other_name>Hexadrol</other_name>
    <other_name>Lokalison-F</other_name>
    <other_name>Loverine</other_name>
    <other_name>Methylfluorprednisolone</other_name>
    <other_name>Millicorten</other_name>
    <other_name>Mymethasone</other_name>
    <other_name>Orgadrone</other_name>
    <other_name>Spersadex</other_name>
    <other_name>TaperDex</other_name>
    <other_name>Visumetazone</other_name>
    <other_name>ZoDex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Resection</intervention_name>
    <description>Undergo surgical resection</description>
    <arm_group_label>Arm A (SRS, low dose dexamethasone, surgery)</arm_group_label>
    <arm_group_label>Arm B (SRS, high dose dexamethasone, surgery)</arm_group_label>
    <other_name>Surgical Resection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Radiosurgery</intervention_name>
    <description>Undergo SRS</description>
    <arm_group_label>Arm A (SRS, low dose dexamethasone, surgery)</arm_group_label>
    <arm_group_label>Arm B (SRS, high dose dexamethasone, surgery)</arm_group_label>
    <other_name>Stereotactic External Beam Irradiation</other_name>
    <other_name>stereotactic external-beam radiation therapy</other_name>
    <other_name>Stereotactic Radiation Therapy</other_name>
    <other_name>Stereotactic Radiotherapy</other_name>
    <other_name>stereotaxic radiation therapy</other_name>
    <other_name>stereotaxic radiosurgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;= 18 years&#xD;
&#xD;
          -  Prior or suspected diagnosis of malignancy&#xD;
&#xD;
          -  Brain metastases visible on contrasted magnetic resonance imaging (MRI) brain&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2 (Karnofsky &gt;= 60%)&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks as determined by the investigator&#xD;
&#xD;
          -  Patients must have adequate organ function as determined by Neurosurgery to undergo&#xD;
             surgery&#xD;
&#xD;
          -  Willingness and ability of the subject to comply with scheduled visits, study&#xD;
             procedures, and study restrictions&#xD;
&#xD;
          -  Evidence of a personally signed informed consent indicating that the subject is aware&#xD;
             of the neoplastic nature of the disease and has been informed of the procedures to be&#xD;
             followed, the experimental nature of the therapy, alternatives, potential risks and&#xD;
             discomforts, potential benefits, and other pertinent aspects of study participation&#xD;
&#xD;
          -  Patient must have a negative pregnancy test, be actively taking oral contraceptives or&#xD;
             have undergone a hysterectomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients on any immunosuppressive medication other than dexamethasone&#xD;
&#xD;
          -  Patients who are receiving any other investigational agents or an investigational&#xD;
             device within 21 days before administration of first dose of study drugs&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV)-positive&#xD;
&#xD;
          -  Pregnant or nursing women are excluded&#xD;
&#xD;
          -  Prior whole brain radiotherapy or SRS to the same site planned for surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zachary Buchwald, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University Hospital/Winship Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zachary Buchwald, MD, PhD</last_name>
    <phone>404-778-1790</phone>
    <email>zachary.scott.buchwald@emory.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Emory University Hospital/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zachary Buchwald, MD, PhD</last_name>
      <phone>404-778-1790</phone>
      <email>zachary.scott.buchwald@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Zachary S. Buchwald, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 17, 2021</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2021</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Zachary Buchwald</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Ichthammol</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

